Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
16 nov. 2023 05h14 HE
|
Curium
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...
CURIUM UND PIUR IMAGING KÜNDIGEN EINE PARTNERSCHAFT FÜR DIE SCHILDDRÜSENBILDGEBUNG IN DEUTSCHLAND AN, UM TOMOGRAPHISCHE 3D-ULTRASCHALLÖSUNGEN ZU ERMÖGLICHEN
25 oct. 2023 07h33 HE
|
Curium
BERLIN, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen in der Nuklearmedizin, und PIUR IMAGING, ein europäisches Medizintechnikunternehmen, das bei der Entwicklung von...
Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions
25 oct. 2023 07h33 HE
|
Curium
BERLIN, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, and PIUR IMAGING, a European medical device company at the forefront of pioneering tomographic 3D ultrasound...
Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer
07 sept. 2023 04h25 HE
|
Curium
PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
15 août 2023 10h50 HE
|
Curium
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
28 juil. 2023 06h12 HE
|
Curium
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
25 juil. 2023 06h06 HE
|
Curium
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)
21 juil. 2023 03h30 HE
|
Curium
PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical...
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
26 mai 2023 03h42 HE
|
Curium
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
23 mai 2023 12h57 HE
|
Curium
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...